Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901 commercialization in H2 2026 after the recombinant herpes zoster vaccine candidate demonstrated superior cellular immunogenicity and better safety than GSK’s Shingrix® (HZ/su) in head‑to‑head comparison, while narrowing net losses by 10.6% through improved R&D efficiency.
Financial Performance – FY2025
Metric
FY2025
FY2024
Change
Other Income
RMB 11.0 million
RMB 21.4 million
‑48.4% (decreased gov’t grants/interest)
R&D Expenses
RMB 96.5 million
RMB 135.1 million
‑28.6% (LZ901 trial completion, no share‑based payment costs)
Loss Before Tax
RMB 150.4 million
RMB 168.2 million
‑10.6% (improved efficiency)
Cash & Financial Assets
RMB 419.4 million
–
Strong liquidity position
Unutilized Bank Facilities
RMB 400.3 million
–
Additional financing capacity
Cash Position: Bank balances RMB 95.9 million + financial assets RMB 323.5 million = total RMB 419.4 million
Liquidity Status: “Relatively ample” cash reserves with improved overall financial position
Core Product – LZ901 Shingles Vaccine
Milestone
Status
Timeline
BLA Filing
Submitted to NMPA
January 2025
BLA Acceptance
NMPA accepted
February 2025
Inspections Complete
Clinical + production site
Q3 2025
Regulatory Status
Under NMPA review
Current
Commercialization Target
China Mainland launch
H2 2026
Clinical Evidence
Head‑to‑Head vs. Shingrix®:
Superior cellular immunogenicity in adults ≥50 years
Better safety profile than HZ/su vaccine
US Phase I: Completed September 2025; high‑dose and low‑dose groups demonstrated good safety and immunogenicity vs. placebo – foundation for subsequent US clinical development
Completion no earlier than 2027; world’s first asymmetric CD19/CD3 bispecific
Pre‑Clinical Stage (6)
Asset
Target/Indication
Status Update
Recombinant varicella vaccine
VZV prevention
Pre‑clinical
Recombinant RSV vaccine
RSV lower respiratory tract disease
Pre‑IND stage (Q4 2025)
Recombinant HSV‑1 vaccine
Herpes simplex virus type 1
Pre‑IND filing H2 2027
Recombinant HSV‑2 vaccine
Herpes simplex virus type 2
Pre‑IND filing H2 2026
K333
Bispecific antibody – myeloid leukemia
Pre‑clinical
K1932
Bispecific antibody – B‑cell lymphoma
Pre‑clinical
Operational Infrastructure
Facility
Location
Status
R&D Facility
Yizhuang, Beijing
Operational since August 2025
Manufacturing Facility
Beijing
Trial operation H2 2026
Manufacturing Team
–
48 personnel (as of Dec 2025)
Commercial Team
–
11 personnel (established H2 2025)
Strategic Outlook
LZ901 Commercialization Priority: NMPA approval expected H1 2026 with H2 2026 China launch; manufacturing readiness and 11‑person commercial team scale‑up critical for market entry against established Shingrix® franchise.
R&D Efficiency Focus: 28.6% R&D cost reduction demonstrates disciplined capital allocation post‑LZ901 pivotal trials; future investment weighted toward pre‑clinical advancement and US clinical expansion.
Funding Runway: RMB 419 million cash + RMB 400 million unutilized facilities provides 2.5‑3 years operational runway at current burn rate; potential IPO follow‑on or partnership financing ahead of K3 Phase III initiation.
Forward‑Looking Statements This brief contains forward‑looking statements regarding LZ901 approval timelines, commercialization expectations, and pipeline development milestones. Actual results may differ due to regulatory delays, competitive dynamics, and manufacturing scale‑up challenges.-Fineline Info & Tech
By Fineline Cube 